Table 1.
Demographics data of study participants and headache profiles of patients.
| HV (n = 42) | MOii (n = 41) | MOi (n = 23) | MOH (n = 29) | Triptans (n = 9) | NSAIDs (n = 10) | Both (n = 10) | |
| Women (n) | 26 | 23 | 20 | 23 | 7 | 8 | 8 |
| Age (years) | 32 ± 13 | 34 ± 9 | 33 ± 12 | 35 ± 11 | 32 ± 8 | 35 ± 9 | 34 ± 12 |
| Duration of history of migraine (years) | 18.0 ± 12.7 | 16.7 ± 10.9 | 18.4 ± 11.0 | 18.3 ± 9.6 | 22.4 ± 9.2 | 13.0 ± 13.7 | |
| Days with headache/month (n) | 2.1 ± 1.9 | 3.5 ± 2.3 | 25.9 ± 6.1 | 22.1 ± 6.2 | 25.0 ± 7.4 | 29.4 ± 1.6 | |
| Severity of headache attacks (0-10) | 6.8 ± 0.8 | 7.2 ± 1.2 | 7.2 ± 0.8 | 7.4 ± 1.1 | 7.2 ± 0.5 | 7.1 ± 0.8 | |
| Nausea/vomiting (n) | 25 | 16 | 24 | 8 | 9 | 7 | |
| Photophobia (n) | 37 | 21 | 27 | 8 | 10 | 9 | |
| Phonophobia (n) | 31 | 20 | 27 | 7 | 10 | 10 | |
| Pulsating (n) | 38 | 21 | 26 | 9 | 9 | 8 | |
| Duration of the chronic headache (years) | 3.0 ± 3.2 | 1.9 ± 1.8 | 3.5 ± 3.1 | 3.3 ± 3.9 | |||
| Tablet intake/month (n) | 74.2 ± 80.8 | 28.7 ± 16.3 | 50.5 ± 38.5 | 127.3 ± 106.5 | |||
| Motor threshold (mA) | 8.4 ± 1.3 | 8.6 ± 1.3 | 8.5 ± 1.5 | 8.7 ± 1.2 | 8.8 ± 1.3 | 9.1 ± 1.1 | 8.3 ± 1.1 |
Data expressed as mean ± SD. HV healthy volunteers; MOii episodic migraneurs without aura studied interictally; MOi episodic migraneurs without aura studied ictally; N number of subjects